Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AMJ 9701; Kepivance; Keratinocyte growth factor - Amgen; KGF - Amgen; Recombinant human fibroblast growth factor-7; Recombinant human keratinocyte growth factor; rhFGF-7; rHu-KGF; rhuFGF-7

Latest Information Update: 07 Dec 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Swedish Orphan Biovitrum
  • Class Chemoprotectants; Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stomatitis
  • No development reported Graft-versus-host disease; Inflammatory bowel diseases

Most Recent Events

  • 06 Dec 2016 No recent reports on development identified - Phase-II for Graft-versus-host disease in USA (IV)
  • 18 Jul 2016 Biomarkers information updated
  • 11 Sep 2013 Swedish Orphan Biovitrum amends its licensing agreement to include palifermin development for a potential new indication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top